Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211332 | 0.77 | ALDH1A1 (0.55) | SMN1; SMN2MAPTGAAALDH1A1CYP1A2 | |
| SCHEMBL1357311 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2MAPTGAAALDH1A1CYP1A2 | |
| SCHEMBL766122 | 0.74 | L3MBTL1 (0.58) | SMN1; SMN2MAPTGAAALDH1A1CYP1A2 | |
| SCHEMBL29956155 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2MAPTGAAALDH1A1CYP1A2 | |
| SCHEMBL4444015 | 0.74 | ALDH1A1 (0.47) | SMN1; SMN2MAPTGAAALDH1A1CYP1A2 | |
| SCHEMBL7305154 | 0.71 | PKM (0.43) | PKMMAPTGAAALDH1A1CYP2C19 | |
| SCHEMBL12304006 | 0.71 | SMN1; SMN2 (0.41) | SMN1; SMN2GAAALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL4682271 | 0.71 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTGAAALDH1A1CYP1A2 | |
| SCHEMBL19272985 | 0.70 | POLB (0.37) | — | |
| SCHEMBL21393341 | 0.69 | SMN1; SMN2 (0.40) | SMN1; SMN2GAAALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4408824-A1 | NOVEL INHIBITORS OF CORONAVIRUSES 3-CHYMOTRYPSIN-LIKE PROTEASE | Qubit Pharmaceuticals (FR) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023052638-A1 | NOVEL INHIBITORS OF CORONAVIRUSES 3-CHYMOTRYPSIN-LIKE PROTEASE | QUBIT PHARMACEUTICALS (FR) | 2023-04-06 | — | — | WO | disclosed |
| CN-1297555-C | antagonists of MCP-1 function and methods of use thereof | TELIK INC (US) | 2007-01-31 | — | — | CN | disclosed |
| US-6992086-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6962926-B2 | Antagonist of MCP-1 function, and compositions and methods of use thereof | TELIK, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040198719-A1 | Antagonist of MCP-1 function, and compositions and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| CN-1527831-A | Antagonists of MCP-q function and method of use thereof | ̩ | 2004-09-08 | — | — | CN | disclosed |
| US-20040077680-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | disclosed |
| EP-1358188-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| WO-2002060900-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077680-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | PKM 2756/4885SMN1; SMN2 3238/4885MAPT 2191/4885 |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | PKM 2756/4885SMN1; SMN2 3238/4885MAPT 2191/4885 |
| US-20040198719-A1 | Antagonist of MCP-1 function, and compositions and methods of use thereof | CCR1, CCL11, CCL2 | PKM 4353/4885SMN1; SMN2 2505/4885MAPT 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.